Literature DB >> 12739780

Correlation of rFVIII inactivation with aggregation in solution.

Wei Wang1, Drew N Kelner.   

Abstract

PURPOSE: This study was designed to investigate the stability of recombinant FVIII (rFVIII) in solution at different pHs and to probe the cause(s) of rFVIII inactivation under accelerated storage conditions.
METHODS: Aqueous stability samples of full-length rFVIII at different pHs were incubated at 40 degrees C for several days and analyzed by the one-stage clotting assay. SEC-HPLC, SDS-PAGE, and UV spectrophotometry.
RESULTS: Incubation of liquid rFVIII at 40 degrees C inactivated the protein rapidly and linearly with time on a semi-log scale at all pHs, suggesting a first order or pseudo first order process. A U-shaped relationship was found between the rate constant for loss of rFVIII activity and the solution pH. The minimal rate of inactivation was found between pH 6.6 and 7.0 with a half-life of approximately 4 days. The SEC-HPLC results indicated pH-dependent aggregation of rFVIII during incubation. It was found that the disappearance of monomeric rFVIII by SEC-HPLC correlated with the loss of rFVIII activity (r2 = 0.97). Both the SDS-PAGE and UV results confirmed the aggregation pathway of rFVIII. In addition, the SDS-PAGE results suggest involvement of three aggregation mechanisms--disulfide-bond formation/exchange, non-reducible crosslinking, and physical interactions.
CONCLUSIONS: The full-length rFVIII is unstable in solution at 40 degrees C and loses activity rapidly through a first order or pseudo first order aggregation process, which consists of both physical and chemical pathways. SEC-HPLC may be used in monitoring rFVIII stability studies in lieu of the clotting assay under the incubation conditions used in this study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739780     DOI: 10.1023/a:1023271405005

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  31 in total

1.  Studies of temperature and pH stability of human antihaemophilic factor (AHF) in plasma and in a concentrate.

Authors:  P WOLF
Journal:  Br J Haematol       Date:  1959-04       Impact factor: 6.998

2.  Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII.

Authors:  L Tagliavacca; N Moon; W R Dunham; R J Kaufman
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

Review 3.  Protein aggregation: folding aggregates, inclusion bodies and amyloid.

Authors:  A L Fink
Journal:  Fold Des       Date:  1998

4.  Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.

Authors:  D Eaton; H Rodriguez; G A Vehar
Journal:  Biochemistry       Date:  1986-01-28       Impact factor: 3.162

5.  The size of human factor VIII heterodimers and the effects produced by thrombin.

Authors:  P J Fay; M T Anderson; S I Chavin; V J Marder
Journal:  Biochim Biophys Acta       Date:  1986-06-23

6.  Stability of factor VIII preparation in continuous infusion.

Authors:  U Martinowitz
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

Review 7.  Factor VIII structure and function.

Authors:  P J Fay
Journal:  Thromb Haemost       Date:  1993-07-01       Impact factor: 5.249

8.  Simulations of kinetically irreversible protein aggregate structure.

Authors:  S Y Patro; T M Przybycien
Journal:  Biophys J       Date:  1994-05       Impact factor: 4.033

9.  Recombinant factor VIII SQ--inactivation kinetics in aqueous solution and the influence of disaccharides and sugar alcohols.

Authors:  A Fatouros; T Osterberg; M Mikaelsson
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

10.  Stability of factor VIII concentrates after reconstitution.

Authors:  S Schulman; S Gitel; U Martinowitz
Journal:  Am J Hematol       Date:  1994-03       Impact factor: 10.047

View more
  5 in total

1.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

2.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

3.  Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII).

Authors:  Karthik Ramani; Vivek S Purohit; Razvan D Miclea; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2005-06       Impact factor: 3.534

4.  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.

Authors:  Razvan D Miclea; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

5.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.